We have synthesized and evaluated a series of novel HCV NS3 protease inhibitors with various P4 capping groups, which include urea, carbamate, methoxy-carboxamide, cyclic carbamate and amide, pyruvic amide, oxamate, oxalamide and cyanoguanidine. Most of these compounds are remarkably potent, exhibiting single-digit to sub-nanomolar activity in the enzyme assay and cell-based replicon assay. Selected compounds were also evaluated in the protease-inhibitor-resistant mutant transient replicon assay, and they were found to show quite different potency profiles against a panel of HCV protease-inhibitor-resistant mutants.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bmcl.2012.10.075DOI Listing

Publication Analysis

Top Keywords

novel hcv
8
hcv ns3
8
ns3 protease
8
protease inhibitors
8
inhibitors capping
8
capping groups
8
replicon assay
8
synthesis antiviral
4
antiviral activity
4
activity novel
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!